Comparing robotic platforms for kidney surgery outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates postoperative complications associated with robotic-assisted partial nephrectomy using two surgical platforms: DaVinci and Hugo. Participants will undergo surgery with one of these platforms, and the study aims to identify differences in intra- and post-operative outcomes, including complications, oncological results, and technical aspects. The goal is to provide preliminary insights into the effectiveness and safety of these robotic systems in treating localized kidney tumors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patient aged between 18 and 90 years old;
* patient with localized kidney tumor suitable for partial nephrectomy;
* patient able to understand and sign the informed consent;
* patient compliance with the follow-up program.

Exclusion Criteria:

* patient who do not fall within the inclusion age range;
* patient not suitable for partial nephrectomy;
* patient unable to understand and sign the informed consent;
* patient unable to follow the monitoring program;
* patient refusal to participate to the study.

Where it's running

• Urology Unit, AOUI Verona
  Verona, Vr, Italy Recruiting

Study contacts

• Principal investigator: Alessandro AA Antonelli, MD — Azienda Ospedaliera Universitaria Integrata Verona
• Study coordinator: Alessandro AA Antonelli, MD
• Email: alessandro.antonelli@aovr.veneto.it
• Phone: +39 0458127701

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

• R.E.C.K versus Exparel for pain control during robotic kidney removal

  This will test whether intraoperative R.E.C.K or Exparel gives better pain control and reduces opioid use in adults having robotic partial or radical nephrectomy.

  Recruiting Phase 3 Wake Forest University Health Sciences · Charlotte, North Carolina · NCT07092566

• Olaparib treatment for patients with metastatic kidney cancer and specific gene mutations

  This study is testing if the oral medication olaparib can help people with advanced kidney cancer who have certain gene mutations and have already tried other treatments.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT03786796

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.